奥沙利铂、卡培他滨联合重组改构人肿瘤坏死因子治疗胃癌晚期合并恶性腹水的临床效果观察  

Observation on Clinical Effect of Oxaliplatin,Capecitabine Combined with Recombinant Modified Human Tumor Necrosis Factor in Treatment of Advanced Gastric Cancer Complicated with Malignant Ascites

作　　者：谭智军[1] 罗一民[1] 张建文[1] Tan Zhijun;Luo Yimin;Zhang Jianwen(Department of Gastrointestinal Surgery,First People's Hospital of Chenzhou City,Chenzhou 423000,Hunan Province,China)

机构地区：[1]郴州市第一人民医院胃肠外科,湖南郴州423000

出　　处：《中国社区医师》2025年第8期24-26,共3页Chinese Community Doctors

摘　　要：目的:探讨奥沙利铂、卡培他滨联合重组改构人肿瘤坏死因子治疗胃癌晚期合并恶性腹水的临床疗效。方法:选取2021年7月—2023年7月郴州市第一人民医院收治的胃癌晚期合并恶性腹水的患者80例作为研究对象,随机分为对照组和观察组,各40例。对照组给予奥沙利铂联合卡培他滨治疗,观察组在对照组基础上给予重组改构人肿瘤坏死因子治疗。比较两组治疗效果、生活质量及不良反应发生情况。结果:观察组治疗总有效率和疾病控制率高于对照组(P<0.05)。治疗前,两组Karnofsky功能状态评分标准(KPS)评分比较,差异无统计学意义(P>0.05)。治疗后,观察组KPS评分高于治疗前和同期对照组(P<0.05);对照组KPS评分与治疗前比较,差异无统计学意义(P>0.05)。两组胃肠道反应、骨髓抑制、肝肾损伤、发热发生率对比,差异无统计学意义(P>0.05)。结论:奥沙利铂、卡培他滨联合重组改构人肿瘤坏死因子治疗胃癌晚期合并恶性腹水的临床效果较好,能够有效减少腹水,提高患者生活质量,且安全性较高。Objective:To investigate the clinical efficacy of Oxaliplatin,Capecitabine combined with recombinant modified human tumor necrosis factor in the treatment of advanced gastric cancer complicated with malignant ascites.Methods:A total of 80 patients with advanced gastric cancer complicated with malignant ascites who were admitted to the First People's Hospital of Chenzhou City between July 2021 and July 2023 were enrolled as the study subjects.They were randomly divided into the observation group and control group,with 40 cases in each group.The control group was treated with Oxaliplatin and Capecitabine,and the observation group was treated with recombinant modified human tumor necrosis factor on the basis of control group.The treatment effects,quality of life and occurrence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment and the disease control rate in the observation group were higher than those in the control group(P<0.05).Before treatment,there was no statistically significant difference in the scores of Karnofsky Performance Status Scale(KPS)between the two groups(P>0.05).After treatment,the KPS scores in the observation group were higher than those before treatment and those in the control group during the same period(P<0.05).There was no statistically significant difference in KPS scores in the control group before and after treatment(P>0.05).There was no statistically significant difference in the incidences of gastrointestinal reactions,bone marrow suppression,liver and kidney injury,and fever between the two groups(P>0.05).Conclusion:Oxaliplatin and Capecitabine combined with recombinant modified human tumor necrosis factor in the treatment of advanced gastric cancer complicated with malignant ascites have good clinical effects,and can effectively reduce ascites,improve the quality of life of patients,and have high safety.

关 键 词：重组改构人肿瘤坏死因子 恶性腹水 胃癌晚期 生活质量 

分 类 号：R735.2[医药卫生—肿瘤]